

REMARKS

Claims 29-33, 39-42 and 52 are pending. Claims 29-31, 40-42 and 52 have been amended, and claims 33 and 39 have been canceled without prejudice.

Claims 29-33, 39-42 and 52 were rejected under 35 U.S.C. 112, first paragraph. The specification has been objected to for failing to provide literal support for "a cell-free cartilage membrane."

While Applicants fully disagree with the rejection, the term "cell-free" has been deleted from the claims. Withdrawal of the rejection is therefore requested.

All the remaining rejections are made under 35 U.S.C. § 102. For reasons discussed below, each of these rejections are properly withdrawn. See, for instance, *In re Marshall*, 198 USPQ at 346 ("rejections under 35 USC 102 are proper only when the claimed subject matter is identically disclosed or described in the prior art.").

Claims 29-33 and 52 are rejected under 35 U.S.C. § 102 (b) as being anticipated by U.S. Patent No.5,759,190 (Vibe-Hansen). The Office Action asserts that Vibe-Hansen discloses a cartilage membrane comprising at least one surface part carrying a composition comprising at least one stimulation molecule which induces signal transduction in chondroblast/chondrocytes and which is selected from collagen proteins, proteoglycans and non-collagenous proteins.

Applicants respectfully traverse the rejection. The present invention provides a membrane suitable for use when e.g. chondrocytes are transplanted into a cartilage defect to repair the defect. A membrane as claimed contains specific molecules that stimulate signal transduction in the transplanted chondrocytes whereby hyalin cartilage is formed.

In contrast, Vibe-Hansen relates to transplantation of chondrocytes and describes two different membranes, namely i) a hemostatic barrier serving to block vascular invasion of the cartilage site to be repaired (column 3, line 35-37) and ii) a cell-free barrier which isolates the repair site and keeps **transplanted cells in place** (column 3, line 35-39). To fix the membranes **in place**, Tisseel® was used. Tisseel® is an organic glue that is based on a reaction between clotting proteins (e.g. fibrinogen) and thrombin. When fibrinogen and thrombin react, fibrin is formed as a clot. The Tisseel® employed by Vibe-Hansen et al. is as described in column 5, *i.e.*

"The Tisseel® kit consists of the following components:

Tisseel®, a lyophilized, virus-inactivated Sealer, containing clottable protein, thereof fibrinogen, Plamafibronection (CIC) and Factor NU and Plasminogen.

Aprotenin Solution (bovine)

Thrombin 4 (bovine)

Thrombin 500 (bovine)

Calcium Chloride solution

... The fibrin adhesive or the two-component sealant using Tisseel® kit is combined in the manner according to Immuno AG product insert sheet."

As evident from the data sheets enclosed as Exhibit A, Tisseel® is a two-component sealant, the one component being clottable protein and calcium chloride, and the other component being thrombin and aprotenin. Accordingly, the application of Tisseel® on a hemostatic membrane or a cell-free barrier as described in Vibe-Hansen et al. **results in formation of a sealant**, *i.e.* the clottable protein like fibrinogen has reacted with thrombin to form a fibrin clot. Accordingly, the clottable protein like e.g. fibrinogen as such is not present on the membrane or barrier as it has reacted with thrombin to form long chain of fibrin molecules known as fibrin aggregates or fibrin polymer. Rather, a new macro-molecule has been formed by covalent bondings and this molecules is now different from fibrinogen.

In contrast hereto, a stimulation molecule like e.g. fibrinogen is used in an **unreacted** form in accordance with the present invention.

Moreover, as shown in the paper by Brittberg et al. (Biomaterials, vol. 18 (3) (1997), pp 235-242 – previously filed) Tisseel® impairs the natural repair of the osteochondral defect and, accordingly, Tisseel® cannot have any capacity of inducing signal transduction in chondrocytes resulting in formation of hyalin cartilage. Although Tisseel® contains e.g. fibrinogen, which in the present application is used as a stimulation molecule due to its properties in the present context, the fibrinogen in Tisseel® is reacted with thrombin to form fibrin aggregates, i.e. one or two peptides have been removed by means of thrombin (cf. Merck index 4103 relating to fibrin) and covalent bondings have been established.

Due to the fact that clottable protein like e.g. fibrinogen as such is not present in the membrane or barrier described by Vibe-Hansen et al. and the fact that Tisseel® has been found to impair the natural repair of an osteochondral defect, the proteins in Tisseel® **cannot be stimulation molecules** as claimed herein in the present invention.

Additionally, independent claim 29 has been amended to incorporate features of former claim 39, which former claim was not rejected over Vibe-Hansen.

In view thereof, reconsideration and withdrawal of the rejection are requested.

Claims 29, 31, 32, and 52 are rejected under 35 U.S.C. § 102 (e) as being anticipated by U.S. Patent No. 5,876,452 (Athanasίου). The Office Action asserts that Athanasίου discloses a cell-free cartilage membrane (implant) and kit comprising at least one surface part carrying a composition comprising at least one stimulation molecule, which is selected from collagen proteins, proteoglycans and non-collagenous proteins.

Applicants traverse the rejection. Athanasίου does not describe a “cartilage membrane, comprising at least one surface part carrying a composition comprising at least one stimulation molecule, which i) comprises at least one RGD motif; ii) is selected from the group consisting of

collagen proteins, proteoglycans, and non-collagenous proteins, wherein the collagen protein is selected from the group consisting of collagen type II, VI, IX and XI; and iii) induces a signal transduction in chondroblasts/chondrocytes resulting in chondroblasts/chondrocytes producing and secreting matrix components that form hyalin cartilage, the cartilage membrane being a natural or synthetic collagen type I membrane or part thereof." Athanasiou nowhere teaches the claimed invention.

Additionally, independent claim 29 has been amended to incorporate features of former claim 39, which former claim was not rejected over Athanasiou.

In view thereof, reconsideration and withdrawal of the rejection are requested.

Claims 29, 31-33, and 52 are rejected under 35 U.S.C. § 102 (e) as being anticipated by U.S. Patent No. 6,080,194 (Pechence). The Office Action incorrectly asserts that Pachence discloses a cell free cartilage membrane and kit comprising at least one surface part carrying a composition comprising at least one stimulation molecule. The rejection is traversed.

Pachene relates to a collagen membrane and a collagen matrix made of collagen I (see Example 1 and 2). However, collagen I is not included in the definition of a stimulation molecule in the sense of the present invention, cf. the amended claim 29. For instance, Type I Collagen is the major component in tissues like bone and connective tissue but is not present in hyaline cartilage. Furthermore, type I collagen is highly present in fibrocartilage, and expressed in increased amount in OA chondrocytes (Lorenz H., Arthritis Res., 2005; Shibakawa A., Osteoarthritis and Cartilage, 2003). This emphasizes that type I collagen is not a stimulation molecule for chondrogenesis and expression of hyaline cartilage.

Pachene does not describe a membrane as claimed in the present invention.

Indeed, independent claim 29 has been amended to incorporate features of former claim 39, which former claim was not rejected over Pachene.

In view thereof, reconsideration and withdrawal of the rejection are requested.

Claims 29-33, 39-42, and 52 are rejected under 35 U.S.C. § 102 (e) as being anticipated by U.S. Patent No. 6,251,143 (Schwartz). The Office Action asserts that Schwartz discloses a membrane having an attachment factor and/or cell cartilage membrane and kit comprising at least one surface part carrying a composition comprising at least one stimulation molecule. The rejection is traversed.

Schwartz reports a certain insert that is made of a bioabsorbable material, which may include a repair factor or attachment factor that is releasably disposed in the insert (column 4, lines 16-31).

The insert of Schwartz et al. is not a membrane as Applicants disclose and claim. In column 3, lines 37-40 of Schwartz et al. it is mentioned that the insert may be a flexible porous film consisting essentially of completely bioabsorbable material. However, there is no reference or indication that such a film firstly should be a natural or synthetic collagen type I membrane or part thereof as claimed in the present invention and secondly, there is no indication that such a film contains a stimulation molecule. On the contrary, the skilled worker would understand that the film only contains the film-forming material. Thirdly, in column 10 of Schwartz et al. is mentioned a number of different materials that are said to be suitable to use as bio-absorbable materials *for* the insert. Such materials include:

"hyaluronic acid (e.g. as a fiber matrix), polyglycolic acid (e.g. as fiber matrix), collagen, including type I collagen (e.g. as a sponge matrix), polylactic acid (e.g. as a fiber matrix), fibrin clot (which can be filled and molded into the delivery unit), collagen gel (which can be overlayed into a polyglycolic acid matrix), polydioxane, polyester, alginate or combinations thereof"

In other words, *there* is no indication that the insert in the form of a film mentioned in column 3 should be made of collagen type I as the collagen is used to form a sponge matrix. Accordingly, Applicants request withdrawal of the rejection and allowance of the claims.

Claims 29-33, 39-42, and 52 are rejected under 35 U.S.C. § 102 (b) as being anticipated by U.S. Patent No. 5,236,447 (Kubo). The rejection is traversed.

Kubo et al relates to woven fabrics and not to a membrane that is a natural or synthetic collagen type I membrane or part thereof. Accordingly, Kubo does not anticipate the present invention. Accordingly, Applicants request withdrawal of the rejection and allowance of the claims.

Claims 29-33, 39-42, and 52 are rejected under 35 U.S.C. § 102 (b) as being anticipated by U.S. Patent No. 5,236,447 (Li). The rejection is traversed.

Li relates to a method for the preparation of a dense collagen membrane especially for use in the oral cavity in connection with periodontal lesions. In column 6, lines 59-70 it is said that the dispersion of collagen used in the claimed method may contain additives, Among others are mentioned glycoproteins such as fibronectin. However, addition of e.g. fibronectin to the dispersion will not result in a membrane containing fibronectin as such due to the fact that the dispersion in a subsequent step is subjected to a cross-linking step involving the use of e.g. formaldehyde or glutaraldehyde (see column 8, lines 18-44). Such a treatment will introduce multiple covalent bondings and change the overall protein structure, function and amino acid sequence related to fibronectin and, accordingly, if fibronectin should have been included in the collagen dispersion, the resulting membrane does not contain any fibronectin, but a crosslinked polypeptide sequence with no secondary or tertiary structures needed for biological activity. Furthermore, the polypeptide will no longer contain any ROD sequence but a chemical derivation thereof. Accordingly, a membrane according to Li does not contain any stimulation


molecule in the sense of the present invention. Accordingly, Applicants request withdrawal of the rejection and allowance of the claims.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Date: May 2, 2005

Customer No.: 21874

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'SE Patton', is written over a horizontal line.

Stephana E. Patton (Reg. No. 50,373)
Peter F. Corless (Reg. No. 33,860)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Telephone: 617-439-4444
Facsimile: 617-439-4170

THE MERCK INDEX

AN ENCYCLOPEDIA OF
CHEMICALS, DRUGS, AND BIOLOGICALS

THIRTIETH EDITION

Editorial Staff

Marydele J. O'Neil, *Senior Editor*

Ann Smith, *Senior Associate Editor*

Patricia E. Heckelman, *Associate Editor*

John R. Obenchain Jr., *Editorial Assistant*

Jo Ann R. Gallipeau, *Technical Assistant*

Mary Ann D'Alecca, *Administrative Associate*

Susan Budavari, *Editor Emeritus*

Published by
Merck Research Laboratories
Division of

MERCK & CO., INC.
Whitchose Station, NJ


2001

Fibroin

4101

include sesquiterpene lactones such as pulegone. J. Hylands, D. M. Hylands in *Development of Drugs in Medicine*, J. W. Corradi et al., Eds. (1978) Lachester, 1986) pp 100-104. Inhibition of prostaglandin synthesis by feverfew extract: H. O. J. Collier et al. 722 (1980). Effect on human platelet phospholipase. Heja, J. M. Bailey, *ibid.* 1054 (1981). *idem*, *Proc. Leukotrienes Med.* 8, 653 (1982); J. K. Thakkar et al. *Biophys. Acta* 750, 134 (1983). Inhibition of platelet activity: S. Heptinstall et al. *Lancet* 1, 1071 (1983). *Heptinstall et al.*, *J. Pharm. Pharmacol.* 39, 289 (1987). Anti-secretory activity study: W. A. G. et al., *ibid.* 38, 709 (1986). Clinical trials in migraine: E. S. Johnson et al., *ibid.* 38, 709 (1986). Use of oil extract in migraine: E. S. Johnson et al., *US 4788433* (1988 to R. P. Scherer). Review of possible side effects: C. A. Baldwin et al., *ibid.* 38 (1987).


Fexofenadine. [83799-24-0] α , α -Dimethyl-4-[(4-hydroxydiphenylmethyl)-1-piperidinyl]butyric acid; carboxyterfenadine; terfenadine carboxylic acid. $C_{22}H_{27}NO_4$; mol wt 381.45. C, 76.62%, H, 7.79%, N, 12.76%. Nonsedating-type histamine H₁ antagonist. Prep: A. A. Carr et al., *US 3007442* 4254129 (1980, 1981 both to Richardson-Merrell) on as active metabolite of terfenadine, q.v.; D. A. et al., *Arzneimittel-Forsch.* 32, 1185 (1982). Synthesis: al et al., *J. Org. Chem.* 59, 2620 (1994). HPLC separation: K. Y. Chan et al., *J. Chromatogr.* 571, 1 (1992). Determination in biological fluids: A. Terchie, G. B. A. 694, 219 (1995). Effects on cardiac K⁺ channels: al et al., *Mol. Pharmacol.* 44, 1240 (1993). Comparison of cardiotoxic potential: J. A. Hey et al., *Arch. Sch.* 46, 153 (1996). Clinical pharmacology in children: R. Simons et al., *J. Allergy Clin. Immunol.* 98, 100 (1997).



from methanol-butanone, mp 145-147° (Cm); as white crystals from methanol, mp 142-143° (Karl). Chloride, [153439-40-8] Allegra; Telford, *C₂₂H₂₇NO₄*, mol wt 381.45.

CAT: Antihistaminic.

Flaviridine. [69123-98-4] 1-(2-Deoxy-2-fluoro-5-iodo-2,4,4-trimethyl-1H-pyrimidin-5-yl)-5-iodouracil; 5-iodo-2,4,4-trimethyl-1H-pyrimidin-5-yl-5-iodouracil. FIAU. $C_{10}H_8FIN_2O_2$; mol wt 372.09. C, 27.11%, H, 1.84%, N, 7.53%, O, 21.52%. Viral agent; nucleoside analog with antipneumococcal activity: K. A. Watanabe et al., *J. Med. Chem.* 22, 289 (1979). Antiviral activity: J. M. Colacino, C. Lopez, *Antimicrob. Chemother.* 24, 505 (1981); K. A. Watanabe et al., *ibid.* 23, 45 (1979). Clinical pharmacokinetics: R. et al., *Antimicrob. Ag. Chemother.* 38, 2134 (1994). Evaluation of mechanism of hepatotoxicity: L. et al., *Invest.* 95, 535 (1995). Clinical toxicological profile: al et al., *Transpl. Proc.* 27, 1219 (1995).



Crystals from ethanol, mp 216-217°.

4103. Fibrin. [9001-31-4] Fibrin monomer is fibrinogen from which one or two peptides have been removed by means of thrombin. Laki, Chandrasekhar, *Nature* 197, 1267 (1963). The term fibrin is usually applied to polymerized fibrin monomer. Terminal clotting takes place in four steps: (1) fibrinogen hydrolyzes under the influence of thrombin into fibrin and fibrinopeptide fragments; (2) fibrin forms soft clots which can be readily dispersed; (3) thrombin activates fibrin-stabilizing factor, q.v., an enzyme precursor, present in blood plasma; (4) fibrin in the networks cross-links under the influence of the activated PSF to give the final hard clots. *Chem. & Eng. News* 43, no. 32, 38 (1965); O. D. Ratnoff, H. Bennett, *Science* 179, 1291 (1973). Fibrin occurs in two principal forms, fibrin-I, "insoluble" fibrin, differing from fibrin-II, "soluble" fibrin, by urea solubility as well as other characteristics. Fibrin-I is formed through the reaction of a fibrinogen-like plasma protein, PSF, which in the presence of Ca²⁺ converts what would otherwise be a "soluble" weakly bonded gel into a covalently bonded, insoluble clot. Rosenberg, Carman, *Nature* 204, 994 (1964). Chemical studies of crosslinking segments: Chen, Doolittle, *Proc. Nat. Acad. Sci. USA* 66, 472 (1970); *idem*, *Biochemistry* 10, 4486 (1971); Doolittle et al., *Biochem. Biophys. Res. Commun.* 44, 94 (1971). Reviews: W. H. Neegars, *Fibrinogen* (Harvard University Press, 1962) 728 pp; Laki, Gladner, *Physiol. Rev.* 44, 127 (1964); Lorand, *Fed. Proc.* 24, no. 4, part 1, 784 (1965); A. L. Copley, *Thromb. Res.* 14, 249 (1979). Review of chemistry: several authors, *Thromb. Diath. Haemorrh.*, Suppl. 39 (1970).

4104. Fibrinogen. [9001-32-5] Factor I; Paragen. A plasma glycoprotein belonging structurally to the keratins-myosin group. Synthesized and secreted by hepatic parenchymal cells. Present to the extent of 0.3-0.4 g/100 ml in human plasma. Essential to the clotting of blood. Its synthesis is greatly increased during acute inflammatory challenges. The fibrinogen molecule consists of three peptide chains, α (A), β (B), and γ (C), crosslinked by several disulfide bonds. The mol wt of about 400,000 represents a dimeric form of the molecule. Thrombin releases fibrinopeptides A and B from the N-terminal ends of the α and β chains of fibrinogen in the formation of fibrin during coagulation. Because fibrinogen is less soluble than other plasma proteins it is readily separated by precipitation with sodium chloride: Florkin, *J. Biol. Chem.* 87, 629 (1930); or with ammonium sulfate: Nannings, *Arch. Neer. Physiol.* 28, 241 (1946). Prep: from human plasma: Ekdall et al., *J. Am. Chem. Soc.* 69, 2711 (1947). Purification: Canna et al., *Naturwiss.* 48, 574 (1961). End group determination: Lorand, Middlebrook, *Science* 118, 515 (1953). Structural studies: Schauenstein, *Neurochirurg. Z. Neuroforsch.* 8b, 473 (1953); Ekdall, *J. Polymer Sci.* 12, 231 (1954). Reviews: Scapery, *Physiol. Rev.* 34, 711 (1954); Lorand, *Fed. Proc.* 24, no. 4, part 1, 784 (1965); several authors, *Thromb. Diath. Haemorrh.*, Suppl. 39 (1970); A. L. Copley, *Thromb. Res.* 14, 249 (1979). Fibrinogen has been shown to be the receptor for the endogenous lectin (agglutinin) secreted by activated platelets: T. K. Gartner et al., *Nature* 289, 688 (1981). Review of biosynthesis: G. M. Fuller, D. G. Richardson, *Ann. N.Y. Acad. Sci.* 389, 308-322 (1982). Solubility and in water. Aqueous solutions are viscous. Isoelectric point 5.5. Readily denatured by heating to 56° or higher, and by chemical agents such as ethylenediamine, naphthylquinone sul-

fonate, ninhydrin, and alloxan. Small amounts of papain will clot fibrinogen, but larger amounts will digest the clot.

THROMB CAT: Coagulant (clotting factor).

4105. Fibroblast Growth Factor. [62031-54-3] FGF. Growth stimulatory factor originally isolated from bovine brain and pituitary and found to stimulate DNA synthesis in cultured fibroblast cells. Isulin: D. Gospodarowicz, *Nature* 249, 122 (1974). Mitogenic effect on cultured cell lines and induction of amphibian limb regeneration in vivo: D. Gospodarowicz et al., *Advanc. Metab. Disord.* 8, 301 (1975). Two closely related forms have been identified, known as basic (bFGF) and acidic (aFGF) fibroblast growth factors, having a total amino acid sequence homology of 55%. Both induce the proliferation and differentiation of a wide variety of cell types, including corneal and vascular endothelial cells, myoblasts, chondrocytes, osteoblasts and glial cells. FGF has neurotrophic and angiogenic activity and may play an important role in the wound healing process. Purification of bFGF from pituitary: D. Gospodarowicz, *J. Biol. Chem.* 250, 2515 (1975); from brain: D. Gospodarowicz et al., *ibid.* 253, 3736 (1978). Identification of aFGF from bovine brain: K. A. Thomas et al., *ibid.* 253, 5517 (1978). Comparison of fibroblast growth factors: S. K. Lemmon et al., *J. Cell Biol.* 95, 162 (1982). Purification and characterization of aFGF: K. A. Thomas et al., *Proc. Nat. Acad. Sci. USA* 81, 357 (1984). Identity of bFGF from brain and pituitary: D. Gospodarowicz et al., *ibid.* 6963. Amino acid sequence of bFGF: F. Esch et al., *ibid.* 82, 6507 (1985); of aFGF: G. Gimenez-Gallogo et al., *Science* 230, 1385 (1985); F. Esch et al., *Biochem. Biophys. Res. Commun.* 133, 554 (1985). Possible identity of aFGF with endothelial cell growth factor (ECGF) and eye-derived growth factor-II (EDGF-II): A. B. Schreiber et al., *J. Cell Biol.* 101, 1623 (1985); of bFGF with macrophage-derived growth factor (MDGF): A. Baird et al., *Biochem. Biophys. Res. Commun.* 126, 358 (1985); of FGFs with retinal-derived endothelial cell growth factors: A. Baird et al., *Biochemistry* 24, 7855 (1985). Cloning of cDNA for bovine bFGF: J. A. Abraham et al., *Science* 233, 545 (1986); for human bFGF: T. Kurokawa et al., *FEBS Letters* 213, 189 (1987); M. Iwano et al., *Biochem. Biophys. Res. Commun.* 146, 470 (1987). Expression of a chemically synthesized gene for bioactive bovine aFGF: D. L. Line meyer et al., *Biotechnology* 5, 960 (1987). Receptor binding study: G. Neufeld, D. Gospodarowicz, *J. Biol. Chem.* 261, 5631 (1986). FGF-like factors have been isolated from several human tumor cell lines: R. K. Lobb et al., *Biochem. Biophys. Res. Commun.* 139, 861 (1986); M. Klagsbrun et al., *Proc. Nat. Acad. Sci. USA* 83, 2448 (1986); D. Moscatelli et al., *J. Cell. Physiol.* 129, 273 (1986). FGF has also been shown to be structurally homologous to the protein products of several oncogenes: C. Dickson, G. Peters, *Nature* 326, 833 (1987); M. Taira et al., *Proc. Nat. Acad. Sci. USA* 84, 2980 (1987); P. Dela Bovi et al., *Cell* 50, 729 (1987). Review of tissue distribution and bioactivity of bFGF: A. Baird et al., *Rec. Prog. Horm. Res.* 43, 143-205 (1986). Review of structural characterization and biological functions: D. Gospodarowicz et al., *Endocrine Rev.* 8, 95-114 (1987). Potential role in the control of pituitary and gonadal development: D. Gospodarowicz, N. Ferrara, *J. Neuroendocrinol.* 32, 183-191 (1989). Reviews: K. A. Thomas, G. Gimenez-Gallogo, *Trends Biochem. Sci.* 11, 81-84 (1986); D. Gospodarowicz et al., *Mol. Cell. Endocrinol.* 46, 187-204 (1986); K. A. Thomas, *FASEB J.* 1, 434-440 (1987).

Acidic fibroblast growth factor. [106096-92-8] pI 5.7. Exists in 2 microheterogeneous forms: aFGF-I, a 140 amino acid peptide, mol wt 15,900 daltons, and aFGF-2, an amino truncated form lacking 6 amino terminal residues, mol wt 15,200 daltons.

Basic fibroblast growth factor. [106096-93-9] pI 9.6. 146 amino acid peptide, mol wt ~16,000 daltons. Also exists as an amino truncated form, des 1-15 bFGF, lacking the first 15 amino acid residues.

4106. Fibroin. [9001-76-5] Protein filaments produced by members of the phylum Arthropoda, particularly by certain species belonging to the classes Insecta (insects) and Arachnida (spiders, etc.). Fibroin is the main protein of silk and is secreted

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.